In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to AIM ImmunoTech (AIM), with a price target of $5.00. The company’s shares closed last Tuesday at $2.55.
According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 31.5% and a 52.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Vertex Pharmaceuticals.
AIM ImmunoTech has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s analyst top recommended stocks >>
Based on AIM ImmunoTech’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $45K and GAAP net loss of $3.81 million. In comparison, last year the company earned revenue of $29K and had a GAAP net loss of $2.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AIM ImmunoTech, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Orlando, FL.
